Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation

Ning Li,* Rui Xiong,* Ruyuan He, Bohao Liu, Bo Wang, Qing Geng Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Bo Wang; Qing GengDepartment of Thoracic Surgery, Renm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li N, Xiong R, He R, Liu B, Wang B, Geng Q
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	mangiferin lung injury nlrp3 p65 Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/65ccaf0097c24bb9a766b278a063020f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:65ccaf0097c24bb9a766b278a063020f
record_format	dspace
spelling	oai:doaj.org-article:65ccaf0097c24bb9a766b278a063020f2021-12-02T16:58:44ZMangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation1178-7031https://doaj.org/article/65ccaf0097c24bb9a766b278a063020f2021-05-01T00:00:00Zhttps://www.dovepress.com/mangiferin-mitigates-lipopolysaccharide-induced-lung-injury-by-inhibit-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Ning Li,* Rui Xiong,* Ruyuan He, Bohao Liu, Bo Wang, Qing Geng Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Bo Wang; Qing GengDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan, 430060, People’s Republic of ChinaEmail rmh_wb@whu.edu.cn; gengqingwhu@whu.edu.cnScope: Mangiferin (MF) is a natural phytopolyphenol, which displays potential pharmacological properties involving antibacterial, anti-inflammation, antioxidant and anti-tumor. However, little is known about the roles of MF in lung injury. The aim of this study is to demonstrate the modulatory effects and molecular mechanisms by which MF operates in sepsis-induced lung injury.Methods and Results: To examine the protective properties of MF, an in vivo model of lipopolysaccharide (LPS)-induced lung injury in mice and an in vitro model of LPS-treated J774A.1 cells were established, respectively. The results revealed that MF treatment significantly relieved LPS-induced pathological injury and inflammatory response in murine lung tissues. Meanwhile, MF treatment also inhibited nucleotide-binding oligomerization domain (NOD)-like receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome activation and pyroptosis induced by LPS. In macrophage-specific NLRP3 deficiency mice treated with LPS, MF showed little protective effects. NLRP3 overexpression by adenovirus could also offset the beneficial effects of MF in LPS-treated J774A.1 cells. Furthermore, we found that MF could suppress the expression of NLPR3 and pyroptosis of macrophages by inhibiting the nuclear translocation of the nuclear factor-κB (NF-κB) subunits P50 and P65.Conclusion: MF protects against lung injury and inflammatory response by inhibiting NLRP3 inflammasome activation in a NF-κB-dependent manner in macrophages, which provides a promising therapeutic candidate for the treatment of lung injury.Keywords: mangiferin, lung injury, NLRP3, P65Li NXiong RHe RLiu BWang BGeng QDove Medical Pressarticlemangiferinlung injurynlrp3p65PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 2289-2300 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	mangiferin lung injury nlrp3 p65 Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	mangiferin lung injury nlrp3 p65 Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Li N Xiong R He R Liu B Wang B Geng Q Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation
description	Ning Li,* Rui Xiong,* Ruyuan He, Bohao Liu, Bo Wang, Qing Geng Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Bo Wang; Qing GengDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan, 430060, People’s Republic of ChinaEmail rmh_wb@whu.edu.cn; gengqingwhu@whu.edu.cnScope: Mangiferin (MF) is a natural phytopolyphenol, which displays potential pharmacological properties involving antibacterial, anti-inflammation, antioxidant and anti-tumor. However, little is known about the roles of MF in lung injury. The aim of this study is to demonstrate the modulatory effects and molecular mechanisms by which MF operates in sepsis-induced lung injury.Methods and Results: To examine the protective properties of MF, an in vivo model of lipopolysaccharide (LPS)-induced lung injury in mice and an in vitro model of LPS-treated J774A.1 cells were established, respectively. The results revealed that MF treatment significantly relieved LPS-induced pathological injury and inflammatory response in murine lung tissues. Meanwhile, MF treatment also inhibited nucleotide-binding oligomerization domain (NOD)-like receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome activation and pyroptosis induced by LPS. In macrophage-specific NLRP3 deficiency mice treated with LPS, MF showed little protective effects. NLRP3 overexpression by adenovirus could also offset the beneficial effects of MF in LPS-treated J774A.1 cells. Furthermore, we found that MF could suppress the expression of NLPR3 and pyroptosis of macrophages by inhibiting the nuclear translocation of the nuclear factor-κB (NF-κB) subunits P50 and P65.Conclusion: MF protects against lung injury and inflammatory response by inhibiting NLRP3 inflammasome activation in a NF-κB-dependent manner in macrophages, which provides a promising therapeutic candidate for the treatment of lung injury.Keywords: mangiferin, lung injury, NLRP3, P65
format	article
author	Li N Xiong R He R Liu B Wang B Geng Q
author_facet	Li N Xiong R He R Liu B Wang B Geng Q
author_sort	Li N
title	Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation
title_short	Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation
title_full	Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation
title_fullStr	Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation
title_full_unstemmed	Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation
title_sort	mangiferin mitigates lipopolysaccharide-induced lung injury by inhibiting nlrp3 inflammasome activation
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/65ccaf0097c24bb9a766b278a063020f
work_keys_str_mv	AT lin mangiferinmitigateslipopolysaccharideinducedlunginjurybyinhibitingnlrp3inflammasomeactivation AT xiongr mangiferinmitigateslipopolysaccharideinducedlunginjurybyinhibitingnlrp3inflammasomeactivation AT her mangiferinmitigateslipopolysaccharideinducedlunginjurybyinhibitingnlrp3inflammasomeactivation AT liub mangiferinmitigateslipopolysaccharideinducedlunginjurybyinhibitingnlrp3inflammasomeactivation AT wangb mangiferinmitigateslipopolysaccharideinducedlunginjurybyinhibitingnlrp3inflammasomeactivation AT gengq mangiferinmitigateslipopolysaccharideinducedlunginjurybyinhibitingnlrp3inflammasomeactivation
_version_	1718382269359456256

Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation

Ejemplares similares